Generating human brain organoid data for preclinical drug testing
Brain-drug development is limited by models that do not fully capture human biology. Animal studies and single-time-point assays can miss how living tissue changes with disease or treatment, making it difficult to compare compounds and identify promising candidates before clinical trials.
Vale Biolabs runs studies on human brain organoids to help researchers compare responses to drugs over time. Its structured datasets combine several biological measurements, supporting earlier decisions about which compounds to advance.
What stands out about Vale Biolabs
Venture Kick awarded Vale Biolabs CHF 50,000 in 2026 to support its scalable human-organoid data platform for preclinical drug testing.
Source ↗CEO Ilaria Incaviglia earned a biophysics PhD at ETH Zurich, developing mechanical biosensors for individual living cells.
Source ↗Vale Biolabsfounder Ilaria Incaviglia is an EWOR Fellow, featured in EWOR's July 2026 fellowship update.
Source ↗Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.